MetaCap

Elutia (ELUT) vs ImageneBio (IMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Elutia (ELUT) has outperformed ImageneBio (IMA) over the past year, gaining 52.6% versus a loss of 44.9%. Over five years, ELUT leads with a -82.8% price change compared with -97.9% for IMA. ImageneBio is the larger company by market cap ($48.8 million vs $40.0 million), about 1.2 times the size, while Elutia is growing revenue faster (-15.0% vs -77.1%).

Elutia converts more of its revenue into profit, with a net margin of 434.2% versus -5668.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELUT+52.56%IMA-44.87%
+115%+26%-63%
Nov 21, 20251 yearNov 20, 2026
ELUT-84.48%IMA-97.89%
+47%-29%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELUT versus IMA key metrics
MetricELUTIMA
Share price$0.9001$3.92
Market cap$39.96M$48.83M
1-day change+11.12%0.00%
YTD return+29.88%-43.19%
1-year return+52.56%-44.87%
5-year return-82.76%-97.86%
EPS (TTM)$-0.68$-2.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$12.29M$800.00K
Revenue growth (YoY)-15.03%-77.14%
Net income (latest FY)$53.38M$-45.35M
Gross margin53.66%—
Operating margin-218.91%-6056.38%
Net margin434.23%-5668.63%
52-week high$1.39$7.60
52-week low$0.50$3.00
Distance from 52-week high-35.01%-48.42%
Analyst consensusstrong_buynone
Avg. price target upside+455.49%+359.18%
Average volume185.17K15.86K
Shares outstanding44.40M12.46M
Employees2518
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELUT has outperformed IMA by 97.4 percentage points over the past year.
  • Elutia is more profitable, keeping 434.2 cents of every revenue dollar as net income versus -5668.6 cents for ImageneBio.
  • Elutia grew revenue faster in its latest fiscal year (-15.03% vs -77.14%).

About Elutia

ELUT stock →

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees

About ImageneBio

IMA stock →

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

ELUT vs IMA FAQ

Which is bigger, Elutia or ImageneBio?

ImageneBio (IMA) is larger, with a market capitalization of $48.83M compared with $39.96M for Elutia (ELUT).

Which stock has performed better over the past year, ELUT or IMA?

ELUT returned +52.56% over the past 12 months, compared with -44.87% for IMA (price return, excluding dividends). Past performance does not predict future results.

Are Elutia and ImageneBio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons